- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02228889
RCT of Two Noncrosslinked Porcine Acellular Dermal Matrices in Ab Wall Reconstruction
Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction
Study Overview
Status
Intervention / Treatment
- Procedure: Abdominal wall reconstruction with Strattice
- Other: Assess pain intensity at last office visit preoperatively
- Other: Assess pain interference at last office visit preoperatively
- Other: Assess physical functioning at last office visit preoperatively
- Other: Assess patient quality of life at last office visit preoperatively
- Other: Assess patient pain intensity postoperatively
- Other: Assess pain interference postoperatively
- Other: Assess physical functioning postoperatively
- Other: Assess quality of life postoperatively
- Other: Assess hernia recurrence at 30 days postoperatively
- Other: Assess bulge at 30 days postoperatively
- Other: Assess Surgical Site Occurrences at 30 days postoperatively
- Other: Assess hernia recurrence at 1 year postoperatively
- Other: Assess bulge at 1 year postoperatively
- Other: Assess Surgical Site Occurrences at 1 year postoperatively
- Other: Assess overall complications at 30 days postoperatively
- Other: Assess overall complications at 1 year postoperatively
- Device: Strattice
- Procedure: Abdominal wall reconstruction with XenMatrix
- Device: XenMatrix
Detailed Description
This is a prospective, randomized-controlled trial comparing two porcine acellular matrices in abdominal wall reconstruction. It is single-blind (patients are blinded to the type of mesh used while surgeons are not).
Our goals in this study are:
- PRIMARY OUTCOME: To compare the overall complication rates between two non-cross-linked porcine dermal matrices (XenMatrix and Strattice) at 30 days and 1 year postoperatively
- SECONDARY OUTCOMES
i. To compare the rate of Surgical Site Occurrences (SSOs) between XenMatrix and Strattice in abdominal wall reconstruction at 30 days and 1 year postoperatively
- Infection
- Seroma
- Hematoma
- Wound dehiscence
- Skin necrosis
- Formation of enterocutaneous fistula
- Mesh infection ii. To compare the hernia recurrence rate between XenMatrix and Strattice at 30 days and 1 year postoperatively iii. To compare the bulge rate between XenMatrix and Strattice at 30 days and 1 year postoperatively iv. To compare to changes in patient pain, physical functioning and quality of life after hernia repair between XenMatrix and Strattice, preoperatively, and at 1 year postoperatively A. Pain assessment: Patient Reported Outcomes Measurement Information System (PROMIS) Pain Intensity survey, PROMIS Pain Interference survey B. Physical functioning assessment: PROMIS Physical Function C. Quality of life assessment: Hernia-Related Quality-of-Life (HerQLes) survey
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jeffrey E Janis, MD
- Phone Number: 614-366-1704
- Email: jeffrey.janis@osumc.edu
Study Contact Backup
- Name: Benjamin Sarac, MD
- Phone Number: (614) 293-8566
- Email: Benjamin.Sarac@osumc.edu
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- The Ohio State University Wexner Medical Center
-
Sub-Investigator:
- Benjamin Sarac, MD
-
Principal Investigator:
- Jeffrey E Janis, MD
-
Sub-Investigator:
- Daniel S Eiferman, MD
-
Sub-Investigator:
- Vimal Narula, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age > 18
- Patients presenting for elective hernia repair, with Ventral Hernia Working Group (VHWG) grade 2 or above (Patients with a hernia who need hernia repair due to hernia size, discomfort, risk of bowel incarceration, effect on physical function), and who have comorbidities or contamination making the use of synthetic mesh contraindicated)
- Patients deemed to be good surgical candidates, with no active life-threatening cardiac disease, pulmonary disease, renal disease, hematologic disease (patients who can have a major surgical procedure without an exceedingly high risk of medical complications such as pulmonary edema, myocardial infarction, pulmonary embolism, renal failure, life-threatening bleeding, stroke).
- Patients presenting for resection of large abdominal wall tumors who are expected to undergo have tumor extirpative defect that would require biologic mesh for closure (patients with a large tumor of the abdominal wall who will have a large defect in their fascia after resection, who need biologic mesh for reinforcement).
Exclusion Criteria:
- Known allergy to porcine products
- Active smokers (within the past 4 weeks) presenting for elective hernia repair
- Patients with active life-threatening cardiac disease, pulmonary disease, renal disease, hematologic disease presenting for elective hernia repair
- Patients presenting for emergent hernia repair (in the setting of bowel strangulation, necrosis, penetrating trauma) as it will be difficult to consent those patients for the study preoperatively
- Patients with severe systemic sepsis
- Patients with frank purulence in the wound
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Strattice
Abdominal wall reconstruction with Strattice Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
|
Abdominal wall reconstruction using Strattice
Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
Assess quality of life at 1 year postoperatively using the HerQLes survey
Assess hernia recurrence at 30 days
Assess bulge at 30 days
Assess Surgical Site Occurrences at 30 days
Assess hernia recurrence at 1 year postoperatively
Assess bulge at 1 year postoperatively
Assess Surgical Site Occurrences at 1 year postoperatively
Strattice mesh
|
Experimental: XenMatrix
Abdominal wall reconstruction with XenMatrix Assess pain intensity at last office visit preoperatively Assess pain interference at last office visit preoperatively Assess physical functioning at last office visit preoperatively Assess patient quality of life at last office visit preoperatively Assess patient pain intensity postoperatively Assess pain interference postoperatively Assess physical functioning postoperatively Assess quality of life postoperatively Assess hernia recurrence at 30 days postoperatively Assess bulge at 30 days postoperatively Assess Surgical Site Occurrences at 30 days postoperatively Assess hernia recurrence at 1 year postoperatively Assess bulge at 1 year postoperatively Assess Surgical Site Occurrences at 1 year postoperatively Assess overall complications at 30 days postoperatively Assess overall complications at 1 year postoperatively
|
Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
Assess quality of life at 1 year postoperatively using the HerQLes survey
Assess hernia recurrence at 30 days
Assess bulge at 30 days
Assess Surgical Site Occurrences at 30 days
Assess hernia recurrence at 1 year postoperatively
Assess bulge at 1 year postoperatively
Assess Surgical Site Occurrences at 1 year postoperatively
Abdominal wall reconstruction with XenMatrix
Xenmatrix mesh
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall complication rate at 1 year
Time Frame: 1 year postoperatively
|
Compare the overall complication rates between two non-cross-linked porcine dermal matrices (XenMatrix and Strattice) at 1 year postoperatively
|
1 year postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Surgical Site Occurrences (SSOs) at 1 year
Time Frame: 1 year postoperatively
|
Compare the rate of Surgical Site Occurrences (SSOs) between XenMatrix and Strattice in abdominal wall reconstruction at 1 year postoperatively. These include:
|
1 year postoperatively
|
Hernia recurrence rate at 30 days
Time Frame: 30 days postoperatively
|
30 days postoperatively
|
|
Bulge rate at 30 days
Time Frame: 30 days postoperatively
|
30 days postoperatively
|
|
Overall complication rate at 30 days
Time Frame: 30 days postoperatively
|
Compare the overall complication rates between two non-cross-linked porcine dermal matrices (XenMatrix and Strattice) at 30 days postoperatively
|
30 days postoperatively
|
Rate of Surgical Site Occurrences (SSOs) at 30 days
Time Frame: 30 days postoperatively
|
Compare the rate of Surgical Site Occurrences (SSOs) between XenMatrix and Strattice in abdominal wall reconstruction at 30 days postoperatively. These include:
|
30 days postoperatively
|
Hernia recurrence rate at 1 year
Time Frame: 1 year postoperatively
|
1 year postoperatively
|
|
Bulge rate at 1 year
Time Frame: 1 year postoperatively
|
1 year postoperatively
|
|
Pain intensity preoperatively
Time Frame: At the last office visit before surgery (average of 1-3 weeks before surgery)
|
Measure patient pain intensity of the two groups (XenMatrix and Strattice), at the last office visit before surgery (average of 1-3 weeks before surgery), using the PROMIS Pain Intensity survey
|
At the last office visit before surgery (average of 1-3 weeks before surgery)
|
Pain interference preoperatively
Time Frame: At the last office visit before surgery (average of 1-3 weeks before surgery)
|
Measure patient pain interference of the two groups (XenMatrix and Strattice), at the last office visit before surgery (average of 1-3 weeks before surgery), using the PROMIS Pain Interference survey
|
At the last office visit before surgery (average of 1-3 weeks before surgery)
|
Pain intensity postoperatively
Time Frame: 1 year postoperatively
|
Measure patient pain intensity of the two groups (XenMatrix and Strattice), at 1 year postoperatively, using the PROMIS Pain Intensity survey
|
1 year postoperatively
|
Pain interference postoperatively
Time Frame: 1 year postoperatively
|
Measure patient pain interference of the two groups (XenMatrix and Strattice), at 1 year postoperatively, using the PROMIS Pain Interference survey
|
1 year postoperatively
|
Physical functioning preoperatively
Time Frame: At the last office visit before surgery (average of 1-3 weeks before surgery)
|
Measure physical functioning of the two groups (XenMatrix and Strattice), at the last office visit before surgery (average of 1-3 weeks before surgery), using the PROMIS Physical Function survey
|
At the last office visit before surgery (average of 1-3 weeks before surgery)
|
Physical functioning postoperatively
Time Frame: 1 year postoperatively
|
Measure physical functioning of the two groups (XenMatrix and Strattice), at 1 year postoperatively, using the PROMIS Physical Function survey
|
1 year postoperatively
|
Quality of life preoperatively
Time Frame: At the last office visit before surgery (average of 1-3 weeks before surgery)
|
Measure patient quality of life of the two groups (XenMatrix and Strattice), at the last office visit before surgery (average of 1-3 weeks before surgery), using the HerQLes survey (Hernia Related Quality of Life survey)
|
At the last office visit before surgery (average of 1-3 weeks before surgery)
|
Quality of life postoperatively
Time Frame: 1 year postoperatively
|
Measure patient quality of life of the two groups (XenMatrix and Strattice), at 1 year postoperatively, using the HerQLes survey (Hernia Related Quality of Life survey)
|
1 year postoperatively
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jeffrey E Janis, MD, Ohio State University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Pathological Conditions, Anatomical
- Hernia, Abdominal
- Neoplasms, Connective Tissue
- Digestive System Fistula
- Neoplasms, Fibrous Tissue
- Hernia
- Fistula
- Hernia, Ventral
- Fibroma
- Intestinal Fistula
- Fibromatosis, Abdominal
Other Study ID Numbers
- 2014H0041
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intestinal Fistula
-
University Hospital, AkershusUniversity Hospital, Linkoeping; Region Örebro County; Uppsala University HospitalCompletedPerianal FistulaNorway
-
Zagazig UniversityCompletedTranssphincteric Anal FistulaEgypt
-
London North West Healthcare NHS TrustCompletedFistula in Ano | Ano FistulaUnited Kingdom
-
Rush University Medical CenterTerminatedRectal Fistula | Anal Fistula | Fistula in Ano | Transsphincteric FistulaUnited States
-
Tehran University of Medical SciencesRecruitingFistula PerianalIran, Islamic Republic of
-
Sykehuset Innlandet HFWithdrawn
-
DatabeanThe Insides CompanyRecruitingIleostomy - Stoma | Intestinal Failure | Enterocutaneous FistulaUnited Kingdom, United States
-
The University of Texas Health Science Center,...CENTER FOR CLINICAL AND TRANSLATIONAL SCIENCESRecruiting
-
RedDress Ltd.RecruitingAnal FistulaUnited States, Israel
-
Hospital Clinic of BarcelonaRecruiting
Clinical Trials on Abdominal wall reconstruction with Strattice
-
Hungarian Surgical SocietyCompletedAbdominal HerniaHungary
-
Erasmus Medical CenterJohann Wolfgang Goethe University Hospital; Technical University of Munich; St... and other collaboratorsUnknownHernia of Abdominal Wall | Biologic Mesh | StratticeGermany
-
University of Sao Paulo General HospitalCompletedAbdominal Wall Defect | Infection | Abdominal Wall Fistula | Abdominal Wall InfectionBrazil
-
University of Sao Paulo General HospitalCompletedAbdominal Wall Defect | Infection | Abdominal Wall Hernia | Abdominal Wall Fistula | Abdominal Wall InfectionBrazil
-
LifeCellTerminatedMastectomy and Breast ReconstructionFrance, Germany, United Kingdom
-
University of PrimorskaFotona d.o.o.Completed
-
South Valley UniversityCompletedCommon Bile Duct Injury
-
Duke UniversityLinda Cendales, MD; Kadiyala Ravindra, M.D.; Detlev Erdmann, M.D.RecruitingAbdominal Wall Defect | Abdominal Wall Hernia | Transplant; Failure, Liver | Transplant;Failure,Kidney | Transplant; Failure, Bowel | Abdominal Wall Fistula | Abdominal Wall InjuryUnited States
-
The Cleveland ClinicRecruitingHernia, Abdominal | Hernia, Ventral | Hernia Abdominal WallUnited States
-
Bursa Yüksek İhtisas Education and Research HospitalCompletedLaparoscopy | Abdominal WallTurkey